Literature DB >> 29372949

Antenatal Pertussis Vaccination: Why are General Practitioners Reluctant? A Mixed Methods StudySetting.

A O'Connell1, A Tummon1, K Coleman1, A Jordan1, J McCormack2, M E Kelly2,3.   

Abstract

Pertussis has a disproportionately higher morbidity and mortality in infants less than 3 months of age. International and national guidelines recommend pertussis vaccination during pregnancy, as a safe and effective way to protect these infants. Antenatal pertussis vaccination uptake rates remain suboptimal, with many health care professionals (HCPs) still not recommending it. The reasons underlying this reluctance on behalf of HCPs have not been fully established. This study aims to evaluate the current practice and attitudes of General Practitioners (GPs) with regard to antenatal pertussis vaccination. An embedded mixed method design was used. The response rate was 41% (n=109). 54% of GPs who responded (n=59) routinely recommend antenatal pertussis vaccination. Safety concerns and a sense of isolation emerged as the major qualitative themes. More safety data, adequate funding from the Health Service Executive (HSE) and support from secondary care may help to increase the GP recommendation rate and enhance vaccination uptake in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29372949

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  3 in total

1.  Embedding the delivery of antenatal vaccination within routine antenatal care: a key opportunity to improve uptake.

Authors:  Christopher R Wilcox; Charlotte Woodward; Rebecca Rowe; Christine E Jones
Journal:  Hum Vaccin Immunother       Date:  2019-07-24       Impact factor: 3.452

2.  Current practice and attitudes towards vaccination during pregnancy: a survey of GPs across England

Authors:  Christopher R Wilcox; Paul Little; Christine E Jones
Journal:  Br J Gen Pract       Date:  2020-01-30       Impact factor: 5.386

Review 3.  Key considerations for successful implementation of maternal immunization programs in low and middle income countries.

Authors:  Sushena Krishnaswamy; Philipp Lambach; Michelle L Giles
Journal:  Hum Vaccin Immunother       Date:  2019-01-30       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.